- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
- Interventions
- Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 79
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis, Post-menopausal
- Interventions
- Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 20
- States / cities
- Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more
- Conditions
- Male Osteoporosis
- Interventions
- Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
- Drug · Dietary Supplement
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 85 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Weight Management
- Interventions
- ASC36 Injection A, for subcutaneous use, ASC36 Placebo Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use, ASC36 Placebo Injection B, for subcutaneous use
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Psoriasis
- Interventions
- Placebo, Adalimumab
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615; RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 155
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more
- Conditions
- Behcet's Disease Uveitis
- Interventions
- Placebo, Gevokizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Chicago, Illinois • Ellsworth, Maine + 5 more
- Conditions
- Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 153
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 133 more
- Conditions
- Sars-CoV-2 Infection
- Interventions
- Peginterferon lambda alfa-1a subcutaneous injection, Saline
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- TAK-105-a, TAK-105-a Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Las Vegas, Nevada • Austin, Texas
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Efinopegdutide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
- Conditions
- Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
- Interventions
- mipomersen sodium, placebo
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • Mission Viejo, California + 31 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CZP), Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
- Conditions
- Needle Phobia
- Interventions
- Lidocaine patch 4%, Placebo Patch, 1% Lidocaine Skin Wheal
- Drug · Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- COVID-19, COVID
- Interventions
- Pegylated interferon lambda
- Drug
- Lead sponsor
- Raymond Chung
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Scalp Psoriasis
- Interventions
- Secukinumab 300 mg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
- Conditions
- Diabetic Neuropathy
- Interventions
- JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 23
- States / cities
- Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more
- Conditions
- Endocrine Tumors
- Interventions
- lanreotide (Autogel formulation), Placebo
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
- Conditions
- Inclusion Body Myositis
- Interventions
- ABC008
- Drug
- Lead sponsor
- Abcuro, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Volunteers
- Interventions
- SHP681, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee